Zomedica Corp. (ZOM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1114208,
    "name": "Zomedica Corp.",
    "stock_name": "Zomedica Corp.",
    "full_name": "Zomedica Corp.",
    "name_url": "stocks-analysis/zomedica-corp",
    "exchange": 215,
    "exchangecode": "ASE",
    "country_id": 2,
    "currency": "USD",
    "cmp": "0.11",
    "chg": 0,
    "chgp": "4.03%",
    "dir": 1,
    "prev_price": "0.11",
    "mcapval": "79.38",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "CA98980M1095",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "5.07 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/zomedica-corp-1114208-215&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Zomedica Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zomedica-corp-technically-bullish-or-bearish-3547587",
        "imagepath": "",
        "date": "2025-09-20 19:58:46",
        "description": "As of 12 September 2025, the technical trend for Zomedica Corp. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD and KST are mildly bullish, while the monthly KST is bearish. The RSI is bullish on the weekly timeframe but shows no signal monthly. Moving averages indicate a mildly bearish trend on the daily timeframe. Additionally, the Bollinger Bands reflect a mildly bullish stance weekly but a mildly bearish one monthly. \n\nIn terms of performance, Zomedica has underperformed the S&P 500 across multiple periods, with a 1-week return of -26.68% compared to the S&P's 1.05%, and a 1-year return of -34.04% versus the S&P's 17.14%...."
      },
      {
        "title": "Is Zomedica Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zomedica-corp-overvalued-or-undervalued-3543911",
        "imagepath": "",
        "date": "2025-09-20 18:32:25",
        "description": "As of 1 March 2022, Zomedica Corp. has moved from a \"does not qualify\" rating to \"risky.\" The company appears to be overvalued given its current metrics. Key valuation ratios include a Price to Book Value of 0.33, an EV to EBIT of 0.58, and an EV to EBITDA of 0.77, all indicating a lack of profitability and financial stability. \n\nIn comparison to its peers, Zomedica's P/E ratio is -2.71, while Fusion Pharmaceuticals, Inc. has a P/E of -17.58, and Gossamer Bio, Inc. has a P/E of -4.38, suggesting that Zomedica is not the worst performer in its group but still reflects significant risk. The recent stock performance comparison with the S&P 500 is not available, yet the overall valuation metrics reinforce the notion of Zomedica being overvalued in its current state...."
      }
    ],
    "total": 7,
    "sid": "1114208",
    "stock_news_url": "https://www.marketsmojo.com/news/zomedica-corp-1114208"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Zomedica Corp. technically bullish or bearish?

2025-09-20 19:58:46

As of 12 September 2025, the technical trend for Zomedica Corp. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD and KST are mildly bullish, while the monthly KST is bearish. The RSI is bullish on the weekly timeframe but shows no signal monthly. Moving averages indicate a mildly bearish trend on the daily timeframe. Additionally, the Bollinger Bands reflect a mildly bullish stance weekly but a mildly bearish one monthly. In terms of performance, Zomedica has underperformed the S&P 500 across multiple periods, with a 1-week return of -26.68% compared to the S&P's 1.05%, and a 1-year return of -34.04% versus the S&P's 17.14%....

Is Zomedica Corp. overvalued or undervalued?

2025-09-20 18:32:25

As of 1 March 2022, Zomedica Corp. has moved from a "does not qualify" rating to "risky." The company appears to be overvalued given its current metrics. Key valuation ratios include a Price to Book Value of 0.33, an EV to EBIT of 0.58, and an EV to EBITDA of 0.77, all indicating a lack of profitability and financial stability. In comparison to its peers, Zomedica's P/E ratio is -2.71, while Fusion Pharmaceuticals, Inc. has a P/E of -17.58, and Gossamer Bio, Inc. has a P/E of -4.38, suggesting that Zomedica is not the worst performer in its group but still reflects significant risk. The recent stock performance comparison with the S&P 500 is not available, yet the overall valuation metrics reinforce the notion of Zomedica being overvalued in its current state....

View All News